The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...
More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback